Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of NED-170 for Cancer

Trial Profile

A phase I/II study of NED-170 for Cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NED-170 (Primary)
  • Indications Breast cancer; Cholangiocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2019 According to a NED Biosystems media release, the company plans to initiate the study in 2020
    • 29 Apr 2019 According to a NED Biosystems media release, the company is finalizing the protocol for a phase I/IIA clinical trial to investigate the safety and efficacy of NED-170 in 10 patients with treatment-refractory triple-negative breast cancer and 10 with refractory cholangiocarcinoma. The company expects to begin enrollment in the second half of 2019.
    • 12 Feb 2019 According to a NED Biosystems media release, this study is expected to initiate by 1H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top